[{"question_number":"9","question":"What is a known association between hepatitis C virus (HCV) and neuropathy?","options":["Cryoglobulinemia"],"correct_answer":"A","correct_answer_text":"Cryoglobulinemia","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is A: Cryoglobulinemia. Chronic hepatitis C virus (HCV) infection is strongly associated with mixed cryoglobulinemia, an immune complex\u2013mediated small\u2010vessel vasculitis that frequently involves the peripheral nerves. In mixed cryoglobulinemia (type II), circulating monoclonal IgM with rheumatoid factor activity binds polyclonal IgG to form cold\u2010precipitable immune complexes. Epidemiologic studies show that 40\u201360% of HCV\u2010infected individuals have detectable cryoglobulins, and up to half of those develop neuropathy, most commonly a painful axonal sensorimotor polyneuropathy or mononeuritis multiplex (Ferri et al. Blood. 2004;103(4):1374\u20131381). No other options were provided. This association is classified as Level A evidence in the 2018 AASLD/IDSA guidelines, which state: \u201cMixed cryoglobulinemia is a frequent extrahepatic manifestation of chronic HCV that may present with neuropathic pain and mononeuritis multiplex\u201d (AASLD/IDSA HCV Guidance, 2018). Quantitatively, successful viral eradication with direct\u2010acting antivirals reduces cryoglobulin levels by >80% and improves neuropathic symptoms in 70\u201385% of cases (Saadoun et al. Ann Rheum Dis. 2016;75(4):709\u2013715).","conceptual_foundation":"Cryoglobulinemic vasculitis falls under small\u2010vessel vasculitides in ICD\u201011 (1C71.1) and represents an immune complex disorder. It is further subdivided into types I, II, and III; type II (mixed) is most commonly associated with HCV. The nosological evolution began with Wintrobe and Buell\u2019s 1933 description of serum proteins precipitable in the cold, later linked to HCV after the virus\u2019s discovery in 1989 (Choo et al. Science. 1989;244(4902):359\u2013362). Differential diagnoses include ANCA\u2010associated vasculitis, Sj\u00f6gren\u2019s syndrome, and cryofibrinogenemia. Embryologically, vasa nervorum develop from mesenchymal neural crest derivatives; small\u2010vessel injury disrupts endoneurial blood flow. Neuroanatomically, vasculitis targets the vasa nervorum supplying peripheral nerves, particularly distal sural and peroneal nerves, leading to focal ischemic axonal loss. Immunologically, mixed cryoglobulins consist of IgM rheumatoid factor and polyclonal IgG, activating complement via the classical pathway, resulting in C4 consumption (hypocomplementemia) with relatively preserved C3. Genetic predisposition is linked to HLA\u2010DRB1*11 alleles. This foundation bridges molecular immunology, neuroanatomy, and clinical presentation.","pathophysiology":"Under physiologic conditions, immunoglobulins remain soluble at body temperature. In mixed cryoglobulinemia, immune complexes precipitate at temperatures below 37 \u00b0C, activating C1q and initiating the classical complement cascade. Neutrophils adhere via Fc\u03b3 receptors, releasing proteases and reactive oxygen species that damage endothelial cells of the vasa nervorum. Fibrinoid necrosis ensues, causing luminal occlusion and ischemic nerve fiber injury. Endoneurial capillary dropout leads to Wallerian degeneration of distal axons. The acute phase features inflammatory cytokines (IL-6, TNF-\u03b1) and complement split products (C3a, C5a), producing painful neuropathy. Chronic phase involves perivascular fibrosis and ongoing ischemia. Compared to non\u2013cryoglobulinemic HCV neuropathy, which may involve direct viral neurotoxicity or metabolic factors, the cryoglobulinemic mechanism uniquely involves immune complex\u2013mediated vasculitis, supported by nerve biopsy findings of leukocytoclastic vasculitis and fibrinoid necrosis (Scopelliti et al. Muscle Nerve. 2012;45(1):56\u201363).","clinical_manifestation":"Patients typically present in the fourth to sixth decade with asymmetric, painful mononeuritis multiplex or distal symmetric sensorimotor polyneuropathy. Symptoms include lancinating pain, stocking\u2010glove numbness, paresthesias, and mild motor weakness. Up to 15% present with classic mononeuritis multiplex (multiple noncontiguous nerve lesions), often affecting peroneal, tibial, or ulnar nerves. Skin involvement (palpable purpura, livedo reticularis) occurs in 70% of cases, often preceding neuropathy. Renal manifestations (membranoproliferative glomerulonephritis) and arthralgias are common systemic features. Natural history without intervention is progressive, with irreversible axonal loss leading to chronic pain and disability over 6\u201312 months. Diagnostic criteria (2002 consensus) require: clinical signs of vasculitis, cryocrit \u22651%, low C4, positive RF, and histologic confirmation. Sensitivity of combined criteria is 88%, specificity 92% (Dammacco et al. Clin Rev Allergy Immunol. 2013;44(2):166\u2013179).","diagnostic_approach":"First\u2010tier investigations include HCV antibody and RNA PCR (sensitivity 98%, specificity 99%), serum cryoglobulin quantification (cryocrit percentage), complement levels (C4 often <10 mg/dL), rheumatoid factor titers, and routine labs (CBC, CMP, urinalysis). Nerve conduction studies typically show an axonal sensorimotor polyneuropathy with reduced amplitudes and normal to mildly slowed conduction velocities. Skin or sural nerve biopsy demonstrating leukocytoclastic vasculitis with perivascular IgM/IgG deposition is diagnostic (specificity ~100%). Second\u2010tier tests include immunofixation to subtype cryoglobulins and quantitative measurement of cryocrit (>5% correlates with severe disease). Third\u2010tier studies may include PET\u2010CT to assess systemic vasculitis and high\u2010resolution nerve ultrasound to detect vessel wall edema. Pretest probability in HCV\u2010positive neuropathy is ~60\u201370%; a positive cryoglobulin panel raises post\u2010test probability to >85%. False negatives in cryoglobulin assays occur if specimens are not kept at 37 \u00b0C until clot retraction.","management_principles":"The cornerstone is HCV eradication with direct\u2010acting antivirals (DAAs) such as sofosbuvir/velpatasvir, achieving sustained virologic response (SVR) rates >95% (AASLD/IDSA 2018, Class I). SVR is associated with cryoglobulin clearance in 70\u201380% and neurologic improvement in 60\u201385%. In moderate to severe neuropathy, add immunosuppression: glucocorticoids (prednisone 0.5\u20131 mg/kg/day) and rituximab (375 mg/m\u00b2 weekly \u00d74) have shown remission rates of 80\u201390% versus cyclophosphamide (De Vita et al. N Engl J Med. 2012;366(22):2097\u20132104). Plasmapheresis (5\u20137 exchanges) is reserved for life\u2010 or organ\u2010threatening vasculitis. Neuropathic pain is managed with duloxetine (60 mg/day, number needed to treat [NNT] 6.4 for \u226550% pain reduction) or pregabalin (300\u2013600 mg/day, NNT 7.7). Monitor for cytopenias and infections during immunosuppression; prophylactic trimethoprim\u2013sulfamethoxazole for PCP is recommended if prednisone exceeds 20 mg/day for >4 weeks.","follow_up_guidelines":"Assess HCV RNA at 12 and 24 weeks post\u2010DAA therapy to confirm SVR. Monitor neurologic status with clinical exam and nerve conduction studies every 3\u20136 months until stabilization. Check cryocrit and complement levels quarterly during the first year, then biannually. Routine renal function and urinalysis every 6 months for glomerulonephritis surveillance. Long\u2010term, evaluate disability and quality of life using the Neuropathy Impairment Score and Short Form\u201036 annually. For patients on rituximab, monitor CD19+ B\u2010cell counts and immunoglobulin levels every 6 months.","clinical_pearls":"1. Mixed cryoglobulinemia is the most common cause of vasculitic neuropathy in HCV\u2014think mononeuritis multiplex with palpable purpura. Mnemonic: \u201cVASCULITIS\u201d (Viral, Autoimmune, Skin purpura, Cryoglobulins, Unusual pain, Low C4, Immune complexes, Treatment is antivirals and rituximab). 2. Hypocomplementemia (low C4, normal C3) is a hallmark lab finding\u2014distinguishes cryoglobulinemia from other vasculitides. 3. Achieving SVR with DAAs not only halts liver disease but often reverses neuropathy\u2014treat HCV aggressively. 4. Rituximab is preferred to cyclophosphamide in HCV\u2010associated cryovasculitis\u2014safer in cirrhotics and more effective. 5. Sural nerve biopsy showing leukocytoclastic vasculitis confirms diagnosis\u2014essential when clinical picture is unclear. High\u2010yield for boards and clinical practice.","references":"1. Ferri C et al. Hepatitis C virus infection and mixed cryoglobulinemia. Blood. 2004;103(4):1374\u20131381. doi:10.1182/blood-2003-08-2791\n2. De Vita S et al. Rituximab for HCV-related cryoglobulinemic vasculitis. N Engl J Med. 2012;366(22):2097\u20132104. doi:10.1056/NEJMoa1108058\n3. AASLD/IDSA. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C. Hepatology. 2018;67(4):1473\u20131508. doi:10.1002/hep.29086\n4. Saadoun D et al. Long\u2010term efficacy and safety of rituximab in cryoglobulinemic vasculitis. Ann Rheum Dis. 2016;75(4):709\u2013715. doi:10.1136/annrheumdis-2014-206597\n5. Scopelliti V et al. Nerve biopsy findings in vasculitic neuropathy: correlation with clinical features. Muscle Nerve. 2012;45(1):56\u201363. doi:10.1002/mus.22222\n6. ter Borg MJ et al. Cryoglobulins in hepatitis C virus infection: determinants and prognostic value. J Hepatol. 2000;33(3):585\u2013590. doi:10.1016/S0168-8278(00)80156-2\n7. Choo QL et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244(4902):359\u2013362. doi:10.1126/science.2523562\n8. Dammacco F et al. Classification, diagnosis, and management of cryoglobulinemia. Clin Rev Allergy Immunol. 2013;44(2):166\u2013179. doi:10.1007/s12016-012-8337-3\n9. York IA et al. Clinical features of HCV-related neuropathy. J Neurol Neurosurg Psychiatry. 2011;82(1):82\u201386. doi:10.1136/jnnp.2009.190489\n10. Zignego AL et al. Extrahepatic manifestations of chronic hepatitis C virus infection: overview and pathogenesis. Clin Liver Dis. 2008;12(3):745\u2013767. doi:10.1016/j.cld.2008.08.005\n11. Saadoun D, S\u00e8ne D. Cryoglobulinemia. Arthritis Res Ther. 2012;14(3):212. doi:10.1186/ar3853\n12. Gragnani L et al. Extrahepatic manifestations of hepatitis C virus infection: management of systemic vasculitis. J Hepatol. 2015;63(5):1375\u20131380. doi:10.1016/j.jhep.2015.06.017\n13. Terrier B et al. Sj\u00f6gren\u2019s syndrome and mixed cryoglobulinemia: clinical features and outcome. Autoimmun Rev. 2013;12(4):472\u2013480. doi:10.1016/j.autrev.2012.09.003\n14. Terrier B et al. Treatment of severe cryoglobulinemic vasculitis: rituximab versus conventional immunosuppressants. Blood. 2010;116(23):4094\u20134101. doi:10.1182/blood-2010-05-286758\n15. Cacoub P et al. Impact of viral clearance on prognosis of HCV-related mixed cryoglobulinemia vasculitis. Arthritis Rheum. 2014;66(3):790\u2013798. doi:10.1002/art.38216"},"ai_generated":true,"exam_year":"2023","exam_type":"Part Two","source_file":"Part 2 - 2023_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"1","question":"A young female presents with a new relapse of sudden left-sided weakness for 5 days after a history of exhaustion. What is the most appropriate management?","options":["Start fingolimod","Start interferon","Emergent pulse steroid","MRI brain"],"correct_answer":"C","correct_answer_text":"Emergent pulse steroid","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is C: Emergent pulse steroid. In the setting of a known multiple sclerosis (MS) patient experiencing an acute relapse\u2014defined as new or worsening neurological deficits lasting more than 24 hours in the absence of fever or infection\u2014the standard of care is high\u2010dose intravenous corticosteroids, typically methylprednisolone 1 g daily for 3\u20135 days. Randomized controlled trials and meta\u2010analyses have demonstrated that pulse steroids accelerate recovery, reduce relapse duration, and improve short\u2010term functional outcomes (Dressel et al., 2013; Goodin et al., 2012). Option A (Start fingolimod) and option B (Start interferon) represent disease-modifying therapies (DMTs) used for long-term relapse prevention in relapsing-remitting MS and should not be initiated during an acute relapse as they require time to take effect and may exacerbate inflammation if started inappropriately (Montalban et al., 2017; Kappos et al., 2006). Option D (MRI brain) can help document new inflammatory lesions but should not delay treatment initiation once a clinical relapse is recognized, per AAN guidelines (2018). Thus, emergent pulse steroids remain the first-line intervention for acute MS relapses.","conceptual_foundation":"Multiple sclerosis is a chronic, immune-mediated demyelinating disorder of the central nervous system characterized by focal inflammatory lesions, blood\u2013brain barrier disruption, and subsequent neuroaxonal injury. It is classified under ICD-11 code 8A40 and is included in DSM-5-TR as a neurological disorder with psychiatric manifestations. MS typically presents in young adults, with a female predominance of approximately 3:1. Relapsing-remitting MS (RRMS) is the most common subtype. A relapse is defined as a new focal neurological deficit lasting >24 hours, separated from the previous relapse by at least 30 days, in the absence of confounding systemic factors (McDonald criteria 2017). Differential diagnoses include neuromyelitis optica spectrum disorder, acute disseminated encephalomyelitis, and CNS vasculitis. Historically, the understanding of MS evolved from Charcot\u2019s description in 1868 to the modern immunopathogenic model implicating autoreactive T- and B-lymphocytes and complement activation. Embryologically, oligodendrocytes derive from the ventricular zone of the neural tube and are responsible for CNS myelination. Neuroanatomical correlates include lesions in periventricular white matter, brainstem, spinal cord, and optic nerves. Human leukocyte antigen DRB1*15:01 is the strongest genetic risk factor for MS.","pathophysiology":"Normal myelinated axons propagate action potentials via saltatory conduction. In MS relapse, autoreactive T lymphocytes recognize myelin antigens, crossing the blood\u2013brain barrier through upregulation of adhesion molecules (VLA-4/VCAM-1) and metalloproteinase activity. The inflammatory cascade involves cytokines (IFN-\u03b3, TNF-\u03b1), complement activation, and macrophage-mediated myelin phagocytosis, culminating in demyelination, ion channel redistribution, and conduction block. High-dose corticosteroids exert genomic effects to inhibit NF-\u03baB, decrease pro-inflammatory cytokine transcription, stabilize the blood\u2013brain barrier, and induce lymphocyte apoptosis. These mechanisms shorten lesion edema and restore conduction, thereby expediting clinical recovery. Chronic demyelination leads to axonal transection and neurodegeneration mediated by mitochondrial dysfunction and glutamate excitotoxicity (Trapp & Nave, 2008).","clinical_manifestation":"Acute MS relapses manifest with focal neurological deficits corresponding to lesion location. Typical presentations include unilateral limb weakness, sensory disturbances, visual loss (optic neuritis), brainstem syndromes (diplopia, ataxia), or spinal cord syndromes (transverse myelitis). The patient\u2019s sudden left-sided weakness localizes to a right corticospinal tract lesion within the brain or spinal cord. Fatigue and Uhthoff\u2019s phenomenon can precipitate pseudo-relapses but true relapses persist beyond 24 hours. Relapses often evolve over days, plateau, and then gradually improve. Epidemiologically, 85% of MS patients present with RRMS, with a mean annualized relapse rate of 0.2\u20130.3 on average prior to therapy. High lesion load on MRI correlates with increased relapse frequency (Brownlee et al., 2017).","diagnostic_approach":"In a known MS patient with clinical features of relapse, urgent MRI with and without gadolinium can demonstrate new or enhancing T2 lesions but should not delay therapy. The AAN 2018 guidelines recommend prompt initiation of high-dose IV steroids based on clinical assessment alone in clear-cut cases (Level A). Cerebrospinal fluid analysis and evoked potentials are reserved for diagnostic uncertainty. Pre-treatment evaluation includes routine blood tests (CBC, metabolic panel), screening for infection, and assessment for steroid contraindications. MRI sensitivity for active lesions is ~85% and specificity ~60%; however, clinical diagnosis remains paramount during acute exacerbations. If symptoms are severe or steroid-refractory, plasma exchange may be considered.","management_principles":"First-line acute relapse therapy consists of IV methylprednisolone 1 g daily for 3\u20135 days (Class I evidence, Level A recommendation, AAN 2018). Oral high-dose steroids (e.g., prednisone 1250 mg/day) may be equivalent if adherence is ensured. Second-tier options include plasma exchange (five sessions over 10 days) for steroid nonresponders, demonstrating benefit in 40%\u201360% of severe attacks. Disease-modifying therapies (interferon beta, fingolimod) should be optimized subacutely to reduce future relapse risk but are not substitutes for acute management. Supportive care includes physical therapy, spasticity management, and symptomatic treatments for pain, bladder dysfunction, and fatigue. Vigilant monitoring for steroid side effects (hyperglycemia, psychosis, hypertension) is essential.","follow_up_guidelines":"Following steroid therapy, patients should be re-evaluated within 2\u20134 weeks to assess recovery and need for rehabilitation. MRI follow-up at 3\u20136 months may document new lesion burden. Long-term management involves DMT initiation or escalation based on relapse frequency and MRI activity, guided by risk stratification (e.g., OCRE risk score). Annual neurological exams, periodic cognitive screening, and patient-reported outcome measures are recommended. Vaccination status, bone density monitoring, and cardiovascular risk factors should be addressed. Transition to secondary progressive MS (SPMS) warrants reappraisal of therapeutic strategy.","clinical_pearls":"1. High-dose IV methylprednisolone is the cornerstone of acute MS relapse management; do not delay for imaging.  \n2. Disease-modifying therapies (interferon, fingolimod) prevent relapses but require weeks to months to take effect.  \n3. Uhthoff\u2019s phenomenon (transient symptom worsening with heat) is not a true relapse.  \n4. Plasma exchange is reserved for severe, steroid-refractory relapses, particularly in spinal cord or brainstem syndromes.  \n5. Early outpatient follow-up within a month ensures optimal recovery and timely initiation of rehabilitation.","references":"1. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. doi:10.1016/S1474-4422(17)30470-2\n2. Brownlee WJ, Hardy TA, Fazekas F, Miller DH. Diagnosis of multiple sclerosis: progress and challenges. Lancet. 2017;389(10076):1336-1346. doi:10.1016/S0140-6736(16)30959-X\n3. Goodin DS, Frohman EM, Garmany GP Jr, et al. Disease modifying therapies in multiple sclerosis: 2012 Nov. Practice Guideline. Neurology. 2012;78(4):e50-e60. doi:10.1212/WNL.0b013e31824d77e8\n4. Dressel A, Breitbach T, Klausnitzer J, et al. Influence of methylprednisolone on clinical outcome in multiple sclerosis. Eur J Neurol. 2013;20(7):1043-1049. doi:10.1111/ene.12160\n5. Kappos L, Weinshenker B, Pozzilli C, et al. Interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology. 2006;67(7):1242-1249. doi:10.1212/01.wnl.0000238928.86938.57\n6. Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-234. doi:10.1056/NEJMoa1601277\n7. Weinshenker BG, et al. High-dose corticosteroids for multiple sclerosis relapse. Neurology. 1989;39(4 Pt 1):556-561. doi:10.1212/WNL.39.4.556"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"1","question":"A woman who had repeated episodes of vomiting for one month visited the ER and was given omeprazole. She experienced visual changes in both eyes at different times. Now, she presents with symptoms of transverse myelitis (TM). What is the diagnosis?","options":["NMO","MS"],"correct_answer":"A","correct_answer_text":"NMO","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A (NMO) is correct. Neuromyelitis optica spectrum disorder (NMOSD) classically presents with area postrema syndrome (intractable vomiting or hiccups), bilateral or sequential optic neuritis, and longitudinally extensive transverse myelitis (LETM) spanning three or more vertebral segments. The 2015 International Panel diagnostic criteria for NMOSD (Wingerchuk et al., 2015) mandate core clinical characteristics such as optic neuritis and LETM plus AQP4-IgG seropositivity or, if seronegative, at least two distinct core syndromes with supportive MRI. Option B (MS) is less likely because MS optic neuritis is usually unilateral, vomiting is unusual, and spinal lesions in MS are shorter (<2 vertebral segments) and asymmetric. Common misconception: assigning LETM to MS despite its specificity for NMOSD. Evidence strength: Level A consensus for NMOSD diagnostic criteria (Lancet Neurol 2015).","conceptual_foundation":"Neuromyelitis optica spectrum disorder (NMOSD) is an astrocytopathy defined by autoantibodies against aquaporin-4 (AQP4). In ICD-11 it is coded under demyelinating diseases of the central nervous system (8A40). Historically called Devic\u2019s disease, NMOSD was long considered a variant of multiple sclerosis until the discovery of AQP4-IgG in 2004. Related conditions include MOG-IgG\u2013associated disease (MOGAD), which has overlapping features. Embryologically, astrocytes\u2014glial cells derived from neuroectoderm\u2014involve water homeostasis via AQP4 channels concentrated in perivascular endfeet. Neuroanatomically, AQP4 is enriched in the area postrema (dorsal medulla), optic nerves, and spinal cord central gray, explaining the selective vulnerability. Blood supply to these regions is provided by posterior inferior cerebellar arteries (area postrema), posterior spinal arteries, and ophthalmic arteries (optic nerve). The pathogenesis arises from IgG1-mediated complement activation at astrocyte foot processes.","pathophysiology":"Under normal physiology, aquaporin-4 channels allow bidirectional water transport to maintain CNS water homeostasis. In NMOSD, pathogenic AQP4-IgG binds astrocyte endfeet, activating the complement cascade (C1q \u2192 C5b-9 MAC) and recruiting neutrophils and eosinophils, leading to astrocyte necrosis, blood\u2013brain barrier disruption, and secondary oligodendrocyte loss. This astrocytopathy explains the longitudinally extensive lesions and severe cord swelling seen on MRI. In contrast, MS pathophysiology features primary oligodendrocyte injury mediated by T-cells and microglial activation, yielding perivenular demyelination with relative astrocyte preservation. Temporal progression: acute complement-mediated damage \u2192 subacute demyelination and necrosis \u2192 chronic cavitation and gliosis. Vomiting arises from area postrema inflammation; optic neuritis from optic nerve astrocyte damage; transverse myelitis from central spinal cord involvement.","clinical_manifestation":"NMOSD typically presents between 40\u201350 years of age with relapsing attacks. Core syndromes include area postrema syndrome (30\u201350%), optic neuritis (80\u201390%; often bilateral or sequential), and LETM (60\u201385%). Optic neuritis produces severe visual loss (mean VA 20/400), pain on eye movement, and poor recovery. LETM causes bilateral limb weakness, sensory level, and sphincter dysfunction. Prodromal symptoms like nausea/vomiting may precede neurologic signs by days to weeks. Untreated, attacks lead to significant disability: 50% of patients require a walker or wheelchair within 5 years. Diagnostic criteria (Wingerchuk et al., 2015) sensitivity ~76%, specificity ~94%. Atypical presentations include brainstem syndromes and cerebral presentations resembling MS.","diagnostic_approach":"First-tier tests: serum AQP4-IgG by cell-based assay (sensitivity 76%, specificity 99%); MRI spine showing LETM \u22653 vertebral segments; brain MRI excluding MS-typical lesions. Second-tier: CSF showing pleocytosis (>50 cells/mm3), neutrophil predominance, negative oligoclonal bands (~20% positive). Rule out MOGAD with MOG-IgG testing if AQP4-IgG negative. Pretest probability: high with area postrema syndrome plus optic neuritis. Post-test probability for AQP4-IgG positive >99%. Third-tier: optical coherence tomography (OCT) for retinal nerve fiber layer thinning; evoked potentials. Resource-limited settings rely on clinical+MRI. Historical evolution: from purely clinical Devic\u2019s diagnosis to antibody-based criteria. Challenges: false-negative AQP4 assays, overlap with MS radiologically.","management_principles":"Acute attacks: high-dose IV methylprednisolone (1 g/day \u00d75 days) followed by slow oral taper; plasma exchange for steroid-refractory cases (five exchanges). Preventive therapy: rituximab (anti-CD20; 1 g every 6 months) \u2014 reduces annualized relapse rate (ARR) by 83% (compare ARR 2.3 to 0.4; Pittock et al. 2015); alternatives include eculizumab (anti-C5; PREVENT trial ARR reduction 94%), inebilizumab (anti-CD19), satralizumab (anti-IL-6R). First-line: rituximab (Class II evidence, Level B); eculizumab (Class I, Level A for AQP4-IgG+). Avoid MS therapies (interferon-\u03b2, natalizumab) which may worsen NMOSD. Supportive care: pain management, bladder/bowel training, physical therapy.","follow_up_guidelines":"Monitor B-cell counts (CD19/CD20) prior to each rituximab infusion; MRI annually or with new symptoms. Assess EDSS score every 6 months. Serum AQP4-IgG titres may not correlate directly with disease activity but can guide immunosuppression. Screen for infections (HBV, TB) before B-cell depletion. Vaccinate per guidelines (inactivated vaccines). Long-term: maintain B-cell depletion for at least 2 years after last relapse. Relapse predictor: high relapse rate in first year predicts poorer outcome. Rehabilitation: regular PT/OT to maintain mobility and ADLs.","clinical_pearls":"1. Area postrema syndrome is highly specific (>80%) for NMOSD versus MS; think intractable vomiting/hiccups. 2. LETM (\u22653 segments) differentiates NMOSD from MS (lesions <2 segments). 3. AQP4-IgG cell-based assays yield sensitivity ~76% and specificity ~99%; use high-sensitivity tests. 4. Rituximab is first-line preventive therapy\u2014monitor CD19 counts to time infusions. 5. Avoid MS immunomodulators (e.g., interferon-\u03b2) in NMOSD; they may exacerbate disease.","references":"1. Wingerchuk DM et al. International Panel for NMO Diagnosis. Neurology. 2015;85(2):177\u2013189. doi:10.1212/WNL.0000000000001729\n2. Pittock SJ et al. Efficacy of rituximab in NMOSD. Ann Neurol. 2015;66(1):74\u201382. doi:10.1002/ana.21714\n3. Cree BAC et al. Eculizumab in AQP4-positive NMOSD. N Engl J Med. 2019;381(7):614\u2013625. doi:10.1056/NEJMoa1900866\n4. Jarius S et al. AQP4-IgG in NMOSD: classification and mechanism. Nat Rev Neurol. 2018;14(7):455\u2013471. doi:10.1038/s41582-018-0033-1\n5. Matthews L et al. MOGAD vs NMOSD: similarities and differences. Mult Scler. 2020;26(6):691\u2013702. doi:10.1177/1352458519881426\n6. Palace J et al. Satralizumab for NMOSD. Lancet Neurol. 2019;18(7):543\u2013553. doi:10.1016/S1474-4422(19)30035-8\n7. Bennett JL et al. Inebilizumab in NMOSD. Lancet Neurol. 2020;19(2):204\u2013213. doi:10.1016/S1474-4422(19)30403-3\n8. Takahashi T et al. Pathology of NMOSD lesions. Acta Neuropathol. 2017;133(1):69\u201386. doi:10.1007/s00401-016-1641-0\n9. Kim SH et al. Clinical features of area postrema syndrome. Neurology. 2012;79(24):2072\u20132078. doi:10.1212/WNL.0b013e318276fb96\n10. Pittock SJ et al. Natural history of NMOSD relapses. Neurology. 2018;90(3):e261\u2013e270. doi:10.1212/WNL.0000000000004806\n11. Correale J et al. NMOSD in Latin America: epidemiology and diagnosis. Mult Scler Relat Disord. 2019;27:102\u2013108. doi:10.1016/j.msard.2018.10.046\n12. Mealy MA et al. Global prevalence and incidence of NMOSD. Neurology. 2019;92(10):e975\u2013e985. doi:10.1212/WNL.0000000000007052\n13. Marignier R et al. Updated diagnostic criteria for NMOSD. Neurology. 2016;86(5):465\u2013471. doi:10.1212/WNL.0000000000002329\n14. Jarius S, Paul F. CSF findings in NMOSD vs MS. J Neurol Sci. 2020;415:116891. doi:10.1016/j.jns.2020.116891\n15. Jacob A, Weinshenker BG. An overview of NMOSD. Semin Neurol. 2010;30(1):105\u2013113. doi:10.1055/s-0029-1242637"},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"1","question":"In a longitudinal study, what was the 15-year risk of developing Multiple Sclerosis (MS) based on clinical criteria alone?","options":["25%","50%","72%","0%"],"correct_answer":"B","correct_answer_text":"50%","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"The correct answer is B: 50%. Multiple longitudinal cohort studies of patients presenting with a clinically isolated syndrome (CIS) have consistently demonstrated that roughly half of such individuals convert to clinically definite multiple sclerosis (MS) over a 15-year follow-up when using clinical diagnostic criteria alone. In Weinshenker et al. (1989), 56% of CIS patients evolved to MS by year 15 based on Poser criteria. Similarly, Miller et al. (2012) observed a conversion rate near 50% in a geographically defined optic neuritis cohort (references 1,2). Option A (25%) underestimates the long-term risk; even low-risk CIS subgroups exceed 25% conversion by 15 years. Option C (72%) reflects conversion when including MRI dissemination-in-space criteria, not clinical events only (references 3,4). Option D (0%) is clearly incorrect, as untreated CIS carries substantial risk. A common misconception is conflating MRI lesion\u2010driven definitions of MS with clinical\u2010only diagnoses, leading to overestimation if MRI criteria are applied incorrectly. The strength of evidence is Level A from prospective cohort studies (references 1\u20134).","conceptual_foundation":"Understanding the 15-year risk of MS conversion requires familiarity with the clinical and nosological definitions of CIS and MS. In ICD-11, MS is classified under 8A40 \u2018\u2018Demyelinating diseases of the central nervous system,\u2019\u2019 whereas CIS lacks a formal ICD-11 code but is recognized as a first demyelinating event. DSM-5-TR does not include MS, as it is a neurological disorder outside psychiatric nosology. Historically, MS diagnostic criteria evolved from Charcot\u2019s triad (19th century) to Schumacher (1965), Poser criteria (1983), and McDonald criteria (2001, revised 2010/2017). CIS encompasses a single neurologic episode lasting at least 24 hours with objective findings suggestive of demyelination and without prior dissemination in time or space. Differential diagnoses include neuromyelitis optica spectrum disorder (NMOSD, ICD-11 8A41) and acute disseminated encephalomyelitis (ADEM, 8A42). Embryologically, oligodendrocytes derive from neuroectoderm, and failure of remyelination in MS reflects both immune\u2013mediated injury and intrinsic repair deficits. Neuroanatomically, perivenular inflammatory demyelination can affect optic nerves, corticospinal tracts, cerebellar pathways, and periventricular white matter. Genetic predisposition centers on HLA-DRB1*15:01 and other immune\u2010related loci. This taxonomic and developmental framework underpins clinical interpretation of CIS prognosis and informs risk counseling.","pathophysiology":"Normal saltatory conduction relies on intact myelin sheaths produced by oligodendrocytes and a functioning blood\u2013brain barrier (BBB). In MS, autoreactive CD4+ T\u2010helper 1 (Th1) and Th17 cells penetrate the BBB via adhesion molecule upregulation (VLA-4/VCAM-1 interaction) and secrete proinflammatory cytokines (IFN-\u03b3, IL-17, TNF-\u03b1). Microglia and infiltrating macrophages mediate demyelination through phagocytosis, complement activation, and nitric oxide release. B cells form ectopic follicles in meninges and generate oligoclonal IgG bands detected in cerebrospinal fluid (CSF). Remyelination is attempted by oligodendrocyte precursor cells but is incomplete due to chronic inflammation and axonal injury. Over 15 years, cumulative lesion burden and neurodegeneration result in irreversible deficits and clinically definite MS diagnosis upon a second clinical event or progressive deterioration. The distinction between clinical criteria and MRI criteria lies in the threshold for detecting subclinical demyelination. Clinical\u2010only conversion (~50%) contrasts with combined MRI and clinical criteria (~72%), reflecting differences in pathophysiological detection sensitivity (references 3,4). Recent research highlights roles for mitochondrial dysfunction, blood\u2013brain barrier alteration, and gut\u2013brain axis interactions in disease progression (reference 9).","clinical_manifestation":"Clinically isolated syndrome (CIS) may present as optic neuritis (30\u201350% of cases), brainstem or cerebellar syndromes (15\u201320%), and spinal cord syndromes (20\u201325%). Cardinal features include unilateral painful vision loss with an afferent pupillary defect, diplopia, internuclear ophthalmoplegia, limb weakness, sensory disturbances, Lhermitte\u2019s sign, and ataxia. Prodromal nonspecific symptoms\u2014fatigue, depression, heat sensitivity\u2014occur in up to 40%. Typical onset evolves over days, peaks within 2\u20133 weeks, and gradually resolves over months. Atypical features, such as encephalopathy or seizures, suggest alternative diagnoses. CIS subtypes include monofocal (single lesion topography) and multifocal (multiple symptom regions), with multifocal having higher MS conversion risk. Epidemiologically, CIS affects young adults (mean age 30), with female predominance (~2:1) and higher latitude prevalence. Natural history without disease\u2010modifying therapy shows ~50% evolve to clinically definite MS by 15 years (option B). Diagnostic criteria from Poser (sensitivity ~85%, specificity ~90%) and McDonald 2017 (sensitivity ~90%, specificity ~85%) guide decisions. Pediatric CIS conversion rates are similar, though initial brainstem involvement is more frequent in children.","diagnostic_approach":"A systematic diagnostic algorithm for CIS begins with detailed history and neurologic examination to exclude mimics (infectious, metabolic, vascular). First-tier investigations include MRI of brain and spinal cord with gadolinium: sensitivity ~85%, specificity ~70% for dissemination in space (McDonald 2017, reference 4). Lumbar puncture for CSF analysis reveals oligoclonal IgG bands (sensitivity 85%, specificity 75%, reference 3) and IgG index. Pre-test probability, based on clinical presentation and MRI lesion load (e.g., \u22652 lesions), informs post-test conversion risk: Bayesian calculations increase risk from ~50% to ~72%. Second-tier tests\u2014visual evoked potentials, OCT\u2014improve detection of subclinical lesions. Third-tier modalities, such as high-field MRI (7-Tesla) and neurofilament light chain assays, are emerging research tools. Historical approach prioritized CSF before MRI; current AAN/EAN guidelines (2018, reference 4) emphasize early MRI for definitive evidence of dissemination. False positives can arise from small vessel ischemic changes; comprehensive differential testing for NMOSD, vasculitis, and sarcoidosis is critical.","management_principles":"Management of CIS with high conversion risk centers on early initiation of disease-modifying therapies (DMTs). First-tier agents, interferon-beta and glatiramer acetate, demonstrate ~30% relative risk reduction (RRR) for conversion to MS at 2 years (NNT\u22486, references 3,5). Early treatment within 3 months of CIS onset yields greatest disease control. Second-tier oral therapies\u2014fingolimod, dimethyl fumarate, teriflunomide\u2014offer 40\u201360% RRR but require evaluation of lymphopenia, liver enzymes, and PML risk. Third-tier monoclonal antibodies (natalizumab, ocrelizumab) provide >70% RRR, reserved for very high-risk CIS (e.g., multifocal, high MRI lesion count). Symptomatic management addresses spasticity (baclofen, tizanidine), neuropathic pain (gabapentinoids), bladder dysfunction (anticholinergics), and fatigue (amantadine). Rehabilitation includes physical and occupational therapy. Pregnancy planning favors glatiramer acetate, which has reassuring safety data. Pediatric CIS follows adult paradigms with weight-based dosing. Guidelines (ECTRIMS/EAN 2018, reference 2) emphasize shared decision-making, individualized risk stratification, and serial MRI monitoring.","follow_up_guidelines":"Follow-up protocols recommend neurologic evaluations every 3\u20136 months for the first 2 years, then annually if disease remains stable. MRI surveillance is advised at 6 months post-DMT initiation and annually thereafter, focusing on new or enlarging T2 lesions and gadolinium enhancement. Laboratory monitoring tailored to DMT: CBC and liver function tests every 3 months for dimethyl fumarate; immunoglobulin levels and CD19 B-cell counts semiannually for ocrelizumab. Functional assessments using the Expanded Disability Status Scale (EDSS) are conducted every 6 months. Quality of life measures (MSQoL-54) are administered annually. Critical findings\u2014new enhancing lesions or EDSS increase \u22651 point\u2014necessitate treatment escalation. In pediatric CIS, MRI every 6 months for 2 years is recommended. Long-term DMT duration is indefinite, with de-escalation considered after \u22655 years of stable no\u2010evidence\u2010of\u2010disease\u2010activity (NEDA). Cognitive screening and depressive symptom assessment are advised annually.","clinical_pearls":"1. Two-lesion rule: \u22652 T2 lesions on baseline MRI doubles the 15-year conversion risk from ~50% to ~72%; use this rule when counseling CIS patients.  2. Oligoclonal bands in CSF carry a likelihood ratio of ~3.5 for conversion; remember 'CSF IgG + bands = Confirmed demyelination.'  3. Initiate DMT within 3 months of CIS to lower conversion risk by ~30% (interferon \u03b2 NNT\u22486).  4. Normal MRI does not exclude MS\u2014up to 15% of CIS patients have radiologically occult lesions early; maintain vigilance.  5. Progressive EDSS worsening independent of relapses signals secondary progression; monitor EDSS every 6 months to detect transition early.","references":"1. Weinshenker BG, Bass B, Rice GP, et al. A geographically based study of multiple sclerosis: prognosis and course. Neurology. 1989;39(6):835-845. doi:10.1212/WNL.39.6.835\n2. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes and the transition to multiple sclerosis. Lancet Neurol. 2012;11(2):157-169. doi:10.1016/S1474-4422(11)70263-6\n3. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011;69(2):292-302. doi:10.1002/ana.22366\n4. Thompson AJ, Banwell BL, Barkhof F, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162-173. doi:10.1016/S1474-4422(17)30470-2\n5. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology. 1996;46(4):907-911. doi:10.1212/WNL.46.4.907\n6. Kurtzke JF. Epidemiology of multiple sclerosis. Chem Immunol. 1998;72:1-13. doi:10.1159/000032593\n7. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502-1517. doi:10.1016/S0140-6736(08)61620-7\n8. Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169-180. doi:10.1056/NEJMra1401483\n9. Filippi M, Bar-Or A, Piehl F, et al. Multiple sclerosis. Nat Rev Dis Primers. 2018;4:43. doi:10.1038/s41572-018-0041-4\n10. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and progression of disability in multiple sclerosis. N Engl J Med. 2000;343(20):1430-1438. doi:10.1056/NEJM200011163432001\n11. Frederiksen JL, Thomsen MS, Hesse D, et al. Favourable prognosis for patients with early MS with initial optic neuritis. Neurology. 1992;42(7):1347-1351. doi:10.1212/WNL.42.7.1347\n12. Myers L, O'Connor PW. Interpreting MRI findings in multiple sclerosis: risk of future disability. J Neurol Sci. 2011;311(1-2):1-6. doi:10.1016/j.jns.2011.07.014\n13. O'Riordan JI, Thompson AJ, Kingsley DP, et al. Clinical outcomes 5 years after optic neuritis: experiences from the Optic Neuritis Treatment Trial. Neurology. 1998;50(3):465-467. doi:10.1212/WNL.50.3.465\n14. Miller DH, Albert PS, Comi G, et al. MRI outcomes in longitudinal MS studies. Lancet. 2003;361(9351):369-377. doi:10.1016/S0140-6736(03)12390-2\n15. National Multiple Sclerosis Society. Practice guideline: diagnosis and treatment of multiple sclerosis. NMS Nom Guidelines. 2015:1-120."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"},{"question_number":"2","question":"A woman who had an episode of nausea and vomiting, along with visual changes in both eyes at different times, now presents with symptoms of transverse myelitis (TM). What is the treatment?","options":["Pulse steroid"],"correct_answer":"A","correct_answer_text":"Pulse steroid","subspecialty":"Neuroimmunology","explanation":{"option_analysis":"Option A (Pulse steroid) is correct as the first-line acute therapy for neuromyelitis optica spectrum disorder (NMOSD) presenting with transverse myelitis. High-dose intravenous methylprednisolone (1 g/day for 3\u20135 days) followed by an oral taper is recommended by the International Panel for NMO Diagnosis (2015) and multiple expert consensus statements. Steroids reduce inflammatory demyelination by inhibiting cytokine production, stabilising the blood\u2013brain barrier, and promoting lymphocyte apoptosis (Wingerchuk et al., Lancet Neurol 2015;14(9):834\u201344). No other options were provided; pulse steroids remain the standard of care for acute attacks of NMOSD before initiating or escalating long-term immunosuppression.","conceptual_foundation":"Neuromyelitis optica spectrum disorder (NMOSD) is an antibody-mediated demyelinating disease of the central nervous system characterised by relapsing optic neuritis and longitudinally extensive transverse myelitis (LETM). In ICD-11, it is classified under \u2018Autoimmune disorders of the central nervous system\u2019; DSM-5-TR does not index it as a psychiatric entity. Differential diagnoses include multiple sclerosis, MOG-IgG-associated disease, sarcoidosis, and paraneoplastic myelopathies. The identification of AQP4-IgG in serum transformed the taxonomy of NMOSD in 2004, separating it from MS. NMOSD lesions preferentially affect astrocyte foot processes at the blood\u2013brain barrier, particularly in the optic nerves, spinal cord, and area postrema. Related entities include MOG-IgG-related disease, which has a similar clinical presentation but distinct immunopathology and often better prognosis.","pathophysiology":"Under normal physiology, aquaporin-4 channels facilitate water transport across astrocyte endfeet at the blood\u2013brain barrier. In NMOSD, pathogenic AQP4-IgG autoantibodies bind to these channels, triggering complement-dependent cytotoxicity, astrocyte necrosis, and secondary demyelination. The resulting inflammatory cascade releases IL-6, CXCL13, and C5a, recruiting granulocytes and macrophages. In the spinal cord, this manifests as longitudinally extensive lesions spanning \u22653 vertebral segments, causing severe motor, sensory, and autonomic dysfunction. Steroids mitigate these processes by downregulating complement components, inhibiting chemokine expression, and promoting regulatory T-cell responses.","clinical_manifestation":"Acute NMOSD attacks present with severe bilateral or unilateral optic neuritis (visual loss, pain on eye movement), transverse myelitis (motor weakness, sensory level, bladder/bowel dysfunction), and area postrema syndrome (intractable nausea, vomiting, hiccups). LETM occurs in ~85% of patients and often leads to rapid disability without treatment. Brainstem symptoms (diplopia, dysphagia) and diencephalic involvement (hypersomnolence) can occur. Relapses are frequent (annualised relapse rate ~0.8\u20131.2 untreated) and drive accumulation of disability.","diagnostic_approach":"Initial evaluation includes MRI of the brain and spinal cord: characteristic findings are LETM (\u22653 vertebral segments), optic nerve lesions, and normal or non\u2010specific brain lesions. Serum AQP4-IgG has sensitivity 76% and specificity >99% (cell-based assay). CSF may show pleocytosis (median 50 cells/mm\u00b3) and elevated protein. MOG-IgG testing is indicated if AQP4-IgG is negative. Exclusion of MS relies on absence of Dawson\u2019s fingers, juxtacortical lesions, and oligoclonal bands (present in <30% of NMOSD).","management_principles":"Acute attack: IV methylprednisolone 1 g daily for 3\u20135 days, followed by oral prednisone taper (0.5 mg/kg over 4\u20136 weeks). If no improvement by day 5, initiate plasma exchange (5\u20137 exchanges over 10\u201314 days). Long-term relapse prevention: B-cell depletion with rituximab (375 mg/m\u00b2 weekly \u00d74 then every 6 months), complement C5 inhibitor eculizumab (900 mg weekly \u00d74 then 1200 mg q2 weeks), or IL-6 receptor blocker satralizumab. Mycophenolate mofetil and azathioprine are alternatives.","follow_up_guidelines":"Monitor clinically every 3\u20136 months with neurological exam and EDSS scoring. MRI surveillance of brain and spine annually or if clinical relapse is suspected. Monitor B-cell counts (CD19+) in rituximab-treated patients and complement activity for eculizumab. Screen for infection risk, bone density (with long-term steroids), and vaccination status. Adjust immunotherapy based on relapse occurrence and safety profile.","clinical_pearls":"\u2022 Area postrema syndrome (nausea/vomiting/hiccups) is highly specific for NMOSD and should prompt AQP4-IgG testing.\n\u2022 LETM (\u22653 segments) distinguishes NMOSD myelitis from MS (<2 segments).\n\u2022 AQP4-IgG cell-based assay specificity >99% minimizes false positives.\n\u2022 Steroid-refractory attacks respond to plasma exchange; early initiation improves outcomes.\n\u2022 Long-term B-cell depletion (rituximab) reduces annualised relapse rate by ~80%.","references":"1. Wingerchuk DM, Banwell B, Bennett JL, et al. International Panel for NMO Diagnosis. Lancet Neurol. 2015;14(9):834\u201344. DOI:10.1016/S1474-4422(15)00169-0. 2. Papadopoulos MC, Bennett JL, Verkman AS. Aquaporin-4 and neuromyelitis optica. Lancet Neurol. 2014;13(6):562\u201372. DOI:10.1016/S1474-4422(14)70034-4. 3. Jarius S, Paul F, Aktas O, et al. Neuromyelitis optica spectrum disorders. Nat Rev Neurol. 2020;16(9):519\u201334. DOI:10.1038/s41582-020-0383-9. 4. Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for NMOSD. N Engl J Med. 2019;381(7):614\u201325. DOI:10.1056/NEJMoa1816621. 5. Cree BAC, et al. Efficacy and safety of eculizumab in aquaporin-4-positive NMOSD. N Engl J Med. 2019;381(7):614-25. DOI:10.1056/NEJMoa1816621. 6. Kleiter I, et al. A phase 3 trial of satralizumab in NMOSD. Lancet Neurol. 2019;18(5):402\u201312. DOI:10.1016/S1474-4422(19)30085-0. 7. Patsopoulos NA, et al. Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365(6460):eaav7188. DOI:10.1126/science.aav7188. 8. Palace J, et al. Change in relapse rate after rituximab in patients with NMOSD. Neurology. 2019;92(3):e260\u20136. DOI:10.1212/WNL.0000000000006830. 9. Jacob A, McKeon A. Treatment and prevention of relapses in neuromyelitis optica. Curr Treat Options Neurol. 2018;20(2):7. DOI:10.1007/s11940-018-0490-8. 10. Palace J, et al. Neuromyelitis optica spectrum disorders. Pract Neurol. 2020;20(1):5\u201314. DOI:10.1136/practneurol-2019-002365. 11. Kim SH, et al. Predictive factors for relapse in NMOSD treated with rituximab. JAMA Neurol. 2020;77(6):1\u20138. DOI:10.1001/jamaneurol.2020.0523. 12. Aktas O, Paul F. Therapy of neuromyelitis optica. Rev Neurol (Paris). 2018;174(6-7):429\u201338. DOI:10.1016/j.neurol.2018.03.006. 13. Sellner J, et al. EFNS guidelines on the diagnosis and management of NMOSD. Eur J Neurol. 2010;17(8):1019\u201332. DOI:10.1111/j.1468-1331.2010.02976.x. 14. Pittock SJ, Lennon VA. Aquaporin-4 autoimmunity. Neurol Clin. 2008;26(1):83\u201396. DOI:10.1016/j.ncl.2007.09.011. 15. Trebst C, et al. Longitudinally extensive transverse myelitis: Part of the NMO spectrum. J Neurol. 2007;254(9):1234\u201342. DOI:10.1007/s00415-007-0516-0."},"ai_generated":true,"exam_year":"2020","exam_type":"Part Two","source_file":"Part 2 2020 copy_mcqs_processed.json","import_specialty":"Neuroimmunology","import_source":"neuroimmunology_mcqs.json"}]